A high-pressure liquid chromatographic method for the determination of norfloxacin or ciprofloxacin concentratioits in body fluids was developed and compared with a standard bioassay. The high-pressure liquid chromatographic assay utilizes a reverse-phase Cls column, an internal standard, and fluorescence detection, with reproducibility studies yielding coefficients of variation ranging from 0.6 to 3.7% and 0.9 to 2.7% for norfloxacin and ciprofloxacin, respectively. Cortelation coefficients with the bioassay were 0.966 for norfloxacin and 0.952 for ciprofloxacin.
Norfloxacin and ciprofloxacin are new fluoroquinolones with appreciable antimicrobial activity against a broad spectrum of both gram-positive and gram-negative organisms (1, 2, 5, 7, 10, 13, 14) . In a recent review article, Hooper and Wolfson (8) reported on the pharmacology and toxicity of the fluoroquinolones in humans. They reported that in patients with severe renal failure, the half-life of norfloxacin is prolonged, and for both ciprofloxacin and norfloxacin there is evidence that clearance involves both glomerular ifitration and renal tubular secretion. Because the accurate measurement of concentrations in body fluids would allow the adjustment of dosage regimens to avoid toxicity in patients with renal failure and to obtain therapeutic levels in patients with decreased gastrointestinal absorption, we developed a high-pressure liquid chromatography (HPLC) assay for norfloxacin and ciprofloxacin and compared it with a standard agar well diffusion assay.
The HPLC was performed with a Waters solvent delivery system (model 6000A; Waters Associates, Inc., Milford, Mass.) at a rate of 2 ml/min and a Waters fluorescence detector (model 420) with excitation and emission wavelengths of 278 and 456 nm, respectively. Analysis was performed on a reverse-phase ,uBondapak C18 column (10 ,um; 15 cin by 3.9 mm; Waters). Samples were injected with a Rheodyne syringe loading sample injector (model 7125) fitted with a 20-j.l loop (Alltech Associates, Inc., Applied Science Div., State College, Pa.). The mobile phase for HPLC analysis was an acetonitrile-tetrabutyl ammonium hydroxide-phosphate buffer (pH 3.0) which was prepared by adding 1.67 ml of o-phosphoric acid (85%; J. T. Baker Chemical Co., Phillipsburg, N.J.), 15 ml of tetrabutylammonium hydroxide (1.54 M; Sigma Chemical Co., St. Louis, Mo.), and 100 ml of acetonitrile to 1 liter of deionized water. The mobile phase was filtered and degassed before use and was stable for at least 2 days when stored at 4°C. All deionized water used in the preparation of reagents was further purified by passage through a Nanopure water purification system (Sybron/Barrstead, Boston, Mass.). ,g/ml. Standard and control sera were dispensed in 0.2-ml aliquots and stored at -70°C. A-56619 (Abbott Laboratories, North Chicago, Ill.), the internal standard, was reconstituted in sterile deionized water to a final concentration of 10 or 100 ,ug/ml, divided into aliquots, and stored at -70°C. Standards for urine assays were prepared as described above in sterile deionized water rather than serum. Prepared standards and controls of norfloxacin, ciprofloxacin, and A-56619 were stable for at least 2 months at -70°C. The standards, the control sera, and the internal standard (A-56619) were thawed on the day of assay and discarded at the end of the day.
Sample preparation for HPLC required the addition of a solution of A-56619 (0.025 ml) containing 10 or 100 ,ug/ml to 0.2 ml of each serum sample, standard, or control serum. Protein precipitation was accomplished by the addition of 0.2 ml of methanol followed by Vortex mixing for 30 s and centrifugation at 5,500 x g for 10 min. The supernatant was removed and passed through a filter (0.45-,um pore size; Gelman Sciences, Inc., Ann Arbor, Mich.), and the filtrate was used for analysis. Urine samples were diluted 1:10 and 1:20 with deionized water before analysis. A 0.2-ml sample of the diluted urine was added to 0.2 ml of deionized water and filtered as described above.
HPLC serum deterrninations were compared with those of a standard microbiological assay. Norfloxacin and ciprofloxacin concentrations in serum were assayed by a modification of the agar well diffusion assay of Bennett et al. (3) by using a clinical isolate of Providencia stuartii as the test organism. The assay medium was antibiotic medium 1 (Difco Laboratories, Detroit, Mich.) to which p-aminobenzoic acid (Sigma), thymidine (Sigma), and P-lactamase (Genzyme Ltd., Maidstone, Kent, England) were added. Standards (0.125, 0.25, 0.5, and 1.0 ,ug/ml) and control serum (0.75 ,ug/ml) were prepared as described above for the HPLC assay, and 50 ,ul of each sample was placed in Raschig rings (6 by 6 mm; SGA Scientific Co. prediffuse at 4°C for 2 h before incubation at 370C for 16 to 24 h. Inhibition zone diameters were measured, and the serum concentration was calculated from the appropriate standard curves.
Typical chromatograms of norfloxacin and the itternal standard and ciprofloxacin and the internal standard are shown in Fig. 1 . The retention times for norfloxacin, ciprofloxacin, and the internal standard (A-56619) were 2.3, 2.7, and 4.0 min, respectively. The absolute recovery of norfloxacin and ciprofloxacin from serum was evaluated by comparing the peak heights from methanol-extracted sera with the peak heights from aqueous solutions of both compounds at the same concentrations. Percent recovery, calculated by dividing the height of the serum sample peak by that of the aqueous sample peak for norfloxacin and ciprofloxacin over the concentration range of 0.25 to 20 ,ug/ml, averaged 89 to 96%, respectively. Standard curves were generated by least-squares linear regression analysis of the ratio of the ciprofloxacin or norfloxacin peak height to that of the internal standard (A-56619). Standard curves for both serum and aqueous solutions containing norfloxacin or ciprofloxacin were linear from 0.125 to 20.0 ,ug/ml. During the 2-month study period, correlation coefficients for the HPLC standard curves ranged from 0.991 to 1.000. Intraday reproducibility studies, evaluated by 10 assays each of 0.15, 0.75, and 1.5 ,ug/ml concentrations of norfloxacin and ciprofloxacin, yielded coefficients of variation of 2.4 and 2.7%, respectively. Interday reproducibility studies, evaluated by assaying these same concentrations 10 times over a 2-month period, were 2.9 and 1.4% for norfloxacin and ciprofloxacin, respectively. Coefficients of variation for control sera evaluated by the bioassay were 6.3% for norfloxacin and ciprofloxacin.
The specificity of the HPLC assay was evaluated through the addition to pooled human serum of 43 potentially interfering compounds. None of the 43 compounds yielded peaks when assayed by the HPLC system. Some of the more commonly administered drugs tested included amikacin, cefotaxime, piperacillin, gentamicin, ticarcillin, tobramycin, chloramphenicol, vancomycin, penicillin, 5-fluorocytosine, acetominophen, salicylate, diazepam, lidocaine, phenobarbital, phenytoin, quinidine, theophylline, and methotrexate. No endogenous interferences were found in serum or urine from patients. The correlation between the HPLC assay and the bioassay for norfloxacin is shown in Fig. 2 . Linear regression analysis of the data yielded a correlation coefficient of 0.9656 for 57 sera assayed by both methods. The slope of the regression line was 0.9522, and the intercept was 0.0094. Similar results were obtained with ciprofloxacin, with a correlation coefficient of 0.9809 for seven sera assayed by both methods. The slope of the regression line was 0.8929, and the intercept was 0.0648. The concentration of ciprofloxacin or norfloxacin in our patient samples ranged from 0.15 to 1.2 ,ug/ml in serum and 8.1 to 43.7 ,ug/ml in urine.
Although several other HPLC assays for ciprofloxacin or norfloxacin have been described (4, 6, 9, 11, 12), most have not incorporated an internal standard (4, 6, 9) or have not been evaluated with specimens from patients on multipledrug regimens (4, 9, 12) . The HPLC method of Boppana and Swanson (4) for norfloxacin determination did not include an internal standard and required a 1-ml sample of serum as well as multiple extractions with methylene chloride and back extraction with sodium hydroxide before analysis. Although the HPLC method of Pauliukonis et al. (12) for norfloxacin determnination included pipemidic acid as an internal standard, we encountered endogenous interferences with pipemidic acid which could not be resolved in nearly all of our patient serum samples. In our search for an internal standard, we found A-56619 to be acceptable. Nix and NOTES co-workers (11) incorporated this compound as an internal standard in their HPLC method for the determination of ciprofloxacin levels; however, their method required a 0.5-ml sample of serum and had a run time greater than 12 min. Using our chromatographic parameters, we were able to decrease both sample size (0.2 ml) and run time (5 min), as well as to incorporate the same assay method for both ciprofloxacin and norfloxacin determinations.
In summary, we describe an accurate, rapid, and reproducible HPLC method for determining the concentrations of norfloxacin and ciprofloxacin in patient specimens. The simplicity of the extraction procedure and rapid run time of 5 min make this assay ideal for larger laboratories or when rapid turnaround time for results is necessary.
